SCHEMBL5546468

SCHEMBL5546468

COc1ccc(Nc2cc(Cc3ccc(F)cc3)cnc2C#N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.47
KDM4E B2RXH2 2/20 0.47
EGFR P00533 2/20 0.43
ERBB3 P21860 1/20 0.43
MAPT P10636 7/20 0.42
HPGD P15428 4/20 0.42
HTT P42858 3/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TP53 P04637 2/20 0.42
MAPK1 P28482 2/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALOX15 P16050 1/20 0.42
KCNH3 Q9ULD8 2/20 0.41
KDR P35968 1/20 0.41
ACP1 P24666 1/20 0.40
ERBB2 P04626 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715551 0.91 NPC1 (0.39) GAAKDM4EEGFRMAPTMEN1
SCHEMBL5545758 0.79 SAE1 (0.45) GAAEGFRERBB3MAPTLMNA
SCHEMBL5547181 0.79 AKR1C3 (0.45) GAAKDM4EEGFRERBB3MAPT
SCHEMBL11031786 0.74 LTA4H (0.42) GAAKDM4EMAPTHPGDLMNA
SCHEMBL5545737 0.73 CHEK1 (0.42) TP53
SCHEMBL5543137 0.72 GRM2 (0.38) MAPTHPGDMAPK1TSHRNPSR1
SCHEMBL4715889 0.72 MEN1 (0.41) MAPTHTTLMNASMN1; SMN2MEN1
SCHEMBL14610811 0.72 RAB9A (0.39) EGFRMAPTHTTSMN1; SMN2MEN1
SCHEMBL4714989 0.70 GRM2 (0.37) GAAKDM4EHPGDERBB2ALDH1A1
SCHEMBL3794098 0.70 LTA4H (0.65) GAAKDM4EMAPTHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 GAA 2514/4885KDM4E 1268/4885EGFR 3914/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 GAA 1077/4885KDM4E 1255/4885EGFR 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.